Advanced breast cancer metastasized in the brain: treatment standards and innovations

Abstract

Breast cancer continues to be a difficult disease to treat due to high rates of metastasis. Metastasis to the brain presents a unique and often overlooked challenge. In this focused review, we discuss the epidemiology of breast cancer and which types frequently metastasize to the brain. Novel treatment approaches are highlighted with supporting scientific evidence. The role of the blood-brain barrier and how it may become altered with metastasis is addressed. We then highlight new innovations for Her2-positive and triple-negative breast cancer. Finally, recent directions for luminal breast cancer are discussed. This review serves to enhance understanding of pathophysiology, spark continued innovation, and provide a user-friendly resource through tables and easy-to-process figures.

Keywords

Breast cancer / innovation / blood-brain barrier / luminal metastasis / new directions

References

[1] DePolo J. Molecular subtypes of breast cancer. Available from: https://www.breastcancer.org/types/molecular-subtypes [Last accessed on 13 June 2023]

[2] Breast cancer molecular subtypes |CTCA| city of hope. Available from: https://www.cancercenter.com/cancer-types/breast-cancer/types/breast-cancer-molecular-types [Last accessed on 13 June 2023]

[3] Kulukian A,Taylor J.Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models.Mol Cancer Ther2020;19:976-87

[4] Most common molecular subtypes of breast cancer |CTCA|. Available from: https://www.cancercenter.com/cancer-types/breast-cancer/types/breast-cancer-molecular-types [Last accessed on 13 June 2023]

[5] Inic Z,Inic M.Difference between luminal a and luminal b subtypes according to Ki-67, tumor size, and progesterone receptor negativity providing prognostic information.Clin Med Insights Oncol2014;8:107-11 PMCID:PMC4167319

[6] Ngamcherdtrakul W,Cruz-Muñoz W.Targeted nanoparticle for co-delivery of HER2 siRNA and a taxane to mirror the standard treatment of HER2+ breast cancer: efficacy in breast tumor and brain metastasis.Small2022;18:e2107550 PMCID:PMC8959011

[7] Nam BH,Han HS.Breast cancer subtypes and survival in patients with brain metastases.Breast Cancer Res2008;10:R20 PMCID:PMC2374976

[8] Wang Y,Liang Y.Breast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies.Br J Cancer2021;125:1056-67 PMCID:PMC8505648

[9] Ding X,Callen E.Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.Nat Commun2016;7:12425 PMCID:PMC4979061

[10] Purrahman D,Saki N,Kurkowska-Jastrzębska I.Involvement of progranulin (PGRN) in the pathogenesis and prognosis of breast cancer.Cytokine2022;151:155803

[11] Slamon DJ,Wong SG,Ullrich A.Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science1987;235:177-82

[12] Andrikopoulou A,Liontos M,Dimopoulos MA.Trastuzumab deruxtecan (DS-8201a): the latest research and advances in breast cancer.Clin Breast Cancer2021;21:e212-9

[13] Cortés J,Chung WP.Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer.N Engl J Med2022;386:1143-54

[14] Ji C,Yuan Y.Novel anti-HER2 antibody-drug conjugates versus T-DM1 for HER2-positive metastatic breast cancer after tyrosine kinase inhibitors treatment.Oncologist2023;28:e859-66

[15] Bredin P,Denduluri N.Systemic therapy for metastatic HER2-positive breast cancer.Semin Oncol2020;47:259-69

[16] Vu T.Trastuzumab: updated mechanisms of action and resistance in breast cancer.Front Oncol2012;2:62 PMCID:PMC3376449

[17] Cameron D,Gelber RD.11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.Lancet2017;389:1195-205 PMCID:PMC5465633

[18] Maximiano S,Guerreiro MP.Trastuzumab in the treatment of breast cancer.BioDrugs2016;30:75-86

[19] Figueroa-Magalhães MC,Connolly R.Treatment of HER2-positive breast cancer.Breast2014;23:128-36 PMCID:PMC4466908

[20] Hudis CA.Trastuzumab-mechanism of action and use in clinical practice.N Engl J Med2007;357:39-51

[21] Yin L,Bian XW.Triple-negative breast cancer molecular subtyping and treatment progress.Breast Cancer Res2020;22:61 PMCID:PMC7285581

[22] Lyons TG.Targeted therapies for triple-negative breast cancer.Curr Treat Options Oncol2019;20:82

[23] Won KA.Triple-negative breast cancer therapy: current and future perspectives (review).Int J Oncol2020;57:1245-61 PMCID:PMC7646583

[24] Plevritis SK,Kurian AW.Association of screening and treatment with breast cancer mortality by molecular subtype in US women, 2000-2012.JAMA2018;319:154-64 PMCID:PMC5833658

[25] Kumar P.An overview of triple-negative breast cancer.Arch Gynecol Obstet2016;293:247-69

[26] O'Shaughnessy J,Pippen JE.Iniparib plus chemotherapy in metastatic triple-negative breast cancer.N Engl J Med2011;364:205-14

[27] Kim DS,Kraus WL.Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.Exp Mol Med2021;53:42-51 PMCID:PMC8080675

[28] Gelmon KA,Mackay H.Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.Lancet Oncol2011;12:852-61

[29] Spring LM,Hutchinson J.Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities.Oncologist2021;26:827-34 PMCID:PMC8488774

[30] Nanda R,Dees EC.Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study.J Clin Oncol2016;34:2460-7 PMCID:PMC6816000

[31] Thomas R,Decock J.Immune checkpoint inhibitors in triple negative breast cancer treatment: promising future prospects.Front Oncol2020;10:600573 PMCID:PMC7947906

[32] Cortes J,Cescon DW.Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer.N Engl J Med2022;387:217-26

[33] Schmid P,Rugo HS.Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer.N Engl J Med2018;379:2108-21

[34] Miles D,André F.LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC).Ann Oncol2020;31:S1147-8

[35] Van Wambeke S, Gyawali B. Atezolizumab in metastatic triple-negative breast cancer-no contradiction in the eyes of a dispassionate observer.JAMA Oncol2021;7:1285-6

[36] Tran B.Luminal-B breast cancer and novel therapeutic targets.Breast Cancer Res2011;13:221 PMCID:PMC3326541

[37] Ignatiadis M.Luminal breast cancer: from biology to treatment.Nat Rev Clin Oncol2013;10:494-506

[38] Gao JJ.Luminal A breast cancer and molecular assays: a review.Oncologist2018;23:556-65 PMCID:PMC5947456

[39] Treatment by cancer type. Available from: https://www.nccn.org/guidelines/category_1 [Last accessed on 13 June 2023]

[40] Bailleux C,Bachelot T.Treatment strategies for breast cancer brain metastases.Br J Cancer2021;124:142-55 PMCID:PMC7782834

[41] Hosonaga M,Arima Y.Molecular and cellular mechanisms underlying brain metastasis of breast cancer.Cancer Metastasis Rev2020;39:711-20 PMCID:PMC7497304

[42] Liang Y,Song X.Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets.Semin Cancer Biol2020;60:14-27

[43] Lah TT,Breznik B.Brain malignancies: glioblastoma and brain metastases.Semin Cancer Biol2020;60:262-73

[44] Lamouille S,Derynck R.Molecular mechanisms of epithelial-mesenchymal transition.Nat Rev Mol Cell Biol2014;15:178-96 PMCID:PMC4240281

[45] Pedrosa RMSM,Soffietti R.Breast cancer brain metastasis: molecular mechanisms and directions for treatment.Neuro Oncol2018;20:1439-49 PMCID:PMC6176797

[46] Shah N,Saralkar P.Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.Pharmacol Res2018;132:47-68 PMCID:PMC5997530

[47] Venishetty VK,Terell-Hall TB.Identification of novel agents for the treatment of brain metastases of breast cancer.Curr Cancer Drug Targets2017;17:479-85 PMCID:PMC5438904

[48] Knier NN,Zhou J,Parsyan A.Preclinical models of brain metastases in breast cancer.Biomedicines2022;10:667 PMCID:PMC8945440

[49] Saura C,Feng YH.Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial.J Clin Oncol2020;38:3138-49

[50] Curigliano G,Borges V.Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.Ann Oncol2022;33:321-9

[51] Deng J,Wang Y.A novel brain-permeant chemotherapeutic agent for the treatment of brain metastasis in triple-negative breast cancer.Mol Cancer Ther2021;20:2110-6 PMCID:PMC8571036

[52] Oehrlich NE,Papendorf F.Clinical outcome of brain metastases differs significantly among breast cancer subtypes.Oncol Lett2017;14:194-200 PMCID:PMC5494902

[53] Peyrat JP,Lefebvre J.Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer.Eur J Cancer1993;29A:492-7

[54] Law JH,Hu K.Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.Cancer Res2008;68:10238-46

[55] Hwang KT,Jung SH.Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database.Breast Cancer Res Treat2018;169:311-22

[56] Bergen ES,Steindl A.Androgen receptor is expressed in breast cancer brain metastases.Appl Immunohistochem Mol Morphol2021;29:728-33

[57] Mercatali L,Miserocchi G.The emerging role of cancer nanotechnology in the panorama of sarcoma.Front Bioeng Biotechnol2022;10:953555 PMCID:PMC9618700

[58] Valencia-Lazcano AA,Pourmadadi M.5-fluorouracil nano-delivery systems as a cutting-edge for cancer therapy.Eur J Med Chem2023;246:114995

[59] Sakhi M,Iqbal Z.Design and characterization of paclitaxel-loaded polymeric nanoparticles decorated with trastuzumab for the effective treatment of breast cancer.Front Pharmacol2022;13:855294 PMCID:PMC8964068

[60] Elhabak M,Mohamed M,Awad GAS.Near IR responsive targeted integrated lipid polymer nanoconstruct for enhanced magnolol cytotoxicity in breast cancer.Sci Rep2020;10:8771 PMCID:PMC7260181

[61] Choi MR,Stanton-Maxey KJ.Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse.Cancer Nanotechnol2012;3:47-54 PMCID:PMC3505533